| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- manufacturers
- KA2507
-
- $35.00
-
2026-07-17
- CAS:1636894-46-6
- Purity: 99.14%
- Supply Ability: 10g
|
| | Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- Basic information |
| Product Name: | Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- | | Synonyms: | Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy-;modulatory,KA 2507,KA-2507,colorectal,Histone deacetylases,immune,cancer,antitumor,KA2507,Inhibitor,melanoma,HDAC,inhibit;Unii-VQ7NU11krm;KA2507, 10 mM in DMSO;KA2507 ，S9934;KA2507 | | CAS: | 1636894-46-6 | | MF: | C16H14N6O2 | | MW: | 322.32 | | EINECS: | | | Product Categories: | | | Mol File: | 1636894-46-6.mol | ![Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- Structure](CAS/20210305/GIF/1636894-46-6.gif) |
| | Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- Chemical Properties |
| density | 1.407±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 66.67 mg/mL (206.84 mM; Need ultrasonic) | | form | Solid | | pka | 8.77±0.10(Predicted) | | color | White to light brown |
| | Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- Usage And Synthesis |
| Uses | KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models[1]. | | in vivo | KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model[1].
KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models[1].
Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I[1].
KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg)[1].
| Animal Model: | Male C57BL/6 mice, B16-F10 melanoma model[1] | | Dosage: | 100 mg/kg, 200 mg/kg, 200 mg/kg | | Administration: | Oral gavage, daily, for 20 days | | Result: | Demonstrated antitumor efficacy. |
| Animal Model: | Male C57BL/6 mice[1] | | Dosage: | 200 mg/kg (Pharmacokinetic Analysis) | | Administration: | Oral administration | | Result: | Oral bioavailability (15%), Cmax (300 ng/mL). |
| | IC 50 | HDAC6: 2.5 nM (IC50); HDAC8: 621 (IC50) | | References | [1] Apostolia M Tsimberidou, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 May 4. DOI:10.1158/1078-0432.CCR-21-0238 |
| | Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- Preparation Products And Raw materials |
|